Blocking neuromuscular junctions with botulinum toxin A injection enhances neurological heterotopic ossification development after spinal cord injury in mice

Marjorie Salga; Hsu-Wen Tseng; Kylie A Alexander; Beulah Jose; Cedryck Vaquette; Charlotte Debaud; Laure Gatin; François Genêt; Jean-Pierre Levesque

doi:10.1016/j.rehab.2019.01.005

Blocking neuromuscular junctions with botulinum toxin A injection enhances neurological heterotopic ossification development after spinal cord injury in mice

Ann Phys Rehabil Med. 2019 May;62(3):189-192. doi: 10.1016/j.rehab.2019.01.005. Epub 2019 Feb 1.

Authors

Marjorie Salga¹, Hsu-Wen Tseng², Kylie A Alexander², Beulah Jose³, Cedryck Vaquette⁴, Charlotte Debaud⁵, Laure Gatin⁶, François Genêt⁷, Jean-Pierre Levesque⁸

Affiliations

¹ END: ICAP U1179 Inserm, UFR des Sciences de la Santé-Simone Veil, Université Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-le-Bretonneux, France; CIC-IT 1429, Department of Physical Medicine and Rehabilitation, Hôpital Raymond-Poincaré, AP-HP, 92380 Garches, France; Stem Cell Biology Laboratory, Cancer Care and Biology Program, Mater Research, University of Queensland, Woolloongabba, Queensland, Australia.
² Stem Cell Biology Laboratory, Cancer Care and Biology Program, Mater Research, University of Queensland, Woolloongabba, Queensland, Australia; School of Medicine, University of Queensland, Herston, Queensland, Australia.
³ Stem Cell Biology Laboratory, Cancer Care and Biology Program, Mater Research, University of Queensland, Woolloongabba, Queensland, Australia.
⁴ Center in Regenerative Medicine, Institute of health of Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Queensland, Australia; School of Dentistry, University of Queensland, Herston, Queensland, Australia.
⁵ END: ICAP U1179 Inserm, UFR des Sciences de la Santé-Simone Veil, Université Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-le-Bretonneux, France.
⁶ END: ICAP U1179 Inserm, UFR des Sciences de la Santé-Simone Veil, Université Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-le-Bretonneux, France; CIC-IT 1429, Department of Orthopedic Surgery, Hôpital Raymond-Poincaré, AP-HP, 92380 Garches, France.
⁷ END: ICAP U1179 Inserm, UFR des Sciences de la Santé-Simone Veil, Université Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-le-Bretonneux, France; CIC-IT 1429, Department of Physical Medicine and Rehabilitation, Hôpital Raymond-Poincaré, AP-HP, 92380 Garches, France; Stem Cell Biology Laboratory, Cancer Care and Biology Program, Mater Research, University of Queensland, Woolloongabba, Queensland, Australia. Electronic address: [email protected].
⁸ Stem Cell Biology Laboratory, Cancer Care and Biology Program, Mater Research, University of Queensland, Woolloongabba, Queensland, Australia; School of Medicine, University of Queensland, Herston, Queensland, Australia. Electronic address: [email protected].

PMID: 30716518
DOI: 10.1016/j.rehab.2019.01.005

No abstract available

Keywords: Botulinum toxin type a; Neurogenic heterotopic ossification; Osteogenesis; Spinal cord injury.

Publication types

Letter

MeSH terms

Animals
Botulinum Toxins, Type A / adverse effects*
Botulinum Toxins, Type A / pharmacology
Disease Models, Animal
Female
Hamstring Muscles / drug effects*
Mice
Mice, Inbred C57BL
Neuromuscular Agents / adverse effects*
Neuromuscular Agents / pharmacology
Neuromuscular Junction / drug effects*
Ossification, Heterotopic / chemically induced*
Spinal Cord Injuries / drug therapy*

Substances

Neuromuscular Agents
Botulinum Toxins, Type A